Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8388156 | 0.81 | LMNA (0.53) | LMNA | |
| SCHEMBL1767004 | 0.81 | TSHR (0.43) | L3MBTL1LMNA | |
| SCHEMBL17289181 | 0.77 | ALDH1A1 (0.39) | L3MBTL1LMNA | |
| SCHEMBL249377 | 0.77 | KEAP1 (0.48) | PTGS2ATMLMNA | |
| SCHEMBL2536687 | 0.76 | PTGS2 (0.41) | PTGS2ATML3MBTL1LMNANPBWR1 | |
| SCHEMBL758323 | 0.70 | ATM (0.66) | PTGS2ATML3MBTL1LMNAAKR1C3 | |
| SCHEMBL458019 | 0.70 | CYP2A6 (0.44) | LMNA | |
| SCHEMBL9720823 | 0.70 | CYP2A6 (0.44) | LMNA | |
| SCHEMBL4463780 | 0.69 | TSHR (0.39) | L3MBTL1 | |
| SCHEMBL2314445 | 0.69 | MAPT (0.35) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408392-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20140378461-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378461-A1 | NOVEL COMPOUNDS | CYP1B1, DDT, CYP51A1 | PTGS2 2402/4885ATM 4810/4885L3MBTL1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.